




RealRate

# PHARMACEUTICAL 2017

Collectar Biosciences Inc.  
Rank 128 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)



# PHARMACEUTICAL 2017

## Collectar Biosciences Inc. Rank 128 of 313

The relative strengths and weaknesses of Collectar Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Collectar Biosciences Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 162% points. The greatest weakness of Collectar Biosciences Inc. is the variable Revenues, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is -119%, being 297% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	12,193
Cost of Goods Sold	0
Intangible Assets	1,675
Liabilities, Current	1,633
Liabilities, Non-Current	152
Other Assets	12
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	3,269
Property and Equipment	1,444
Research and Development	4,750
Revenues	0
Selling, General and Administrative Expense	4,699

Output Variable	Value in 1000 USD
Assets	15,325
Liabilities	1,785
Expenses	9,450
Stockholders Equity	13,540
Net Income	-6,180
Comprehensive Net Income	-6,180
Economic Capital Ratio	-119%

